TheranosticTrials.org

Clinical Trial · NCT04320030

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

Overview

This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and \[18F\]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.

Sponsor

Institut Cancerologie de l'Ouest

Phase

Phase 2

Contacts

Caroline ROUSSEAU, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04320030

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

DPA-714

Isotope(s):
Target(s):
  • TSPO
Ligand Class: Small Molecules

Eligibility

Inclusion

  • And HER2 (Human Epidermal Growth Factor Receptor-2) not amplified or not overexpressed
  • * 18 Years and older
  • And Progesterone receptors \< 10%
  • Triple negative primary breast cancer based on immunohistochemical results as follows:
  • Estrogen receptor \< 10%

Exclusion

  • * Patient with No triple negative breast cancer
  • Treated diabetes with fasting blood glucose \> 10 mmol/L
  • Patient with metastatic breast cancer
  • Patient with inflammatory breast cancer
  • Patient receiving cancer treatments such as chemotherapy, immunotherapy, biologic response modifiers, hormonal therapy, and radiotherapy BEFORE the biopsy and PET scans are performed